The Gemma termination removes near-term pipeline catalysts for a micro-cap biotech with no approved products. Monitor for any restructuring or cash runway update in the next 10-Q. The lease exit saves future rent but the $2.3M fee is material relative to a $19M market cap.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 28 $5.71entry
- T+1 · 6mo ago +1.05%α +0.81% · $5.77
- T+5 · 6mo ago +5.08%α +4.76% · $6.00
- T+20 · 5mo ago −17.69%α −14.54% · $4.70
- T+60 · 3mo ago −22.24%α −23.98% · $4.44
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Passage Bio terminated its research collaboration with Gemma Biotherapeutics for Huntington's disease and epilepsy programs, losing options for four new CNS indications. Separately, the company paid $2.3 million to exit its 37,000 sq ft Philadelphia office lease, consistent with its remote-only model. The Gemma termination removes a key pipeline catalyst for a $19M market cap biotech with no approved products.
Key Facts
- Terminated Gemma Biotherapeutics collaboration covering Huntington's disease and Temporal Lobe Epilepsy programs, plus options for four new CNS indications.
- Paid $2.3 million termination fee to exit 37,000 sq ft office lease at 2005 Market Street, Philadelphia.
- Company operates as remote-only with no headquarters; lease was set to expire December 2031.
- Market cap is approximately $19 million with no disclosed revenue from product sales.
Financial Impact
$2.3 million cash lease termination fee; loss of R&D collaboration value undisclosed
Risk Factors
- Loss of partnered R&D for Huntington's and epilepsy programs may delay or end those programs.
- Cash burn rate unknown; $2.3M lease termination reduces cash reserves.
- No disclosed revenue or near-term catalysts remain visible.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-066956 |
| Document: 0001104659-26-066956-index-headers.html | 0001104659-26-066956 |
| Document: 0001104659-26-066956-index.html | 0001104659-26-066956 |
| Document: 0001104659-26-066956.txt | 0001104659-26-066956 |
Track record
15 reports on PASG
1 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +13.26% at T+20 after the Sep 2, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 6, 202610d ago 8-K Neutral 5/10 Entry $3.98 Now $4.13 +3.90% settles Dec 7
- Oct 13, 20265w ago EFFECT Neutral 3/10 Entry $3.64 to $3.78 Now $4.13 +13.46% ▲ +3.85% +7.46% vs SPY
- Oct 8, 20265w ago S-4/A Bearish 6/10 Entry $3.69 to $3.98 Now $4.13 −11.92% ▼ −7.72% −13.28% vs SPY
- Oct 5, 20266w ago S-4/A Neutral 5/10 Entry $4.08 to $3.41 Now $4.13 +1.23% ▼ −16.47% −13.56% vs SPY
- Sep 21, 20268w ago S-4/A Neutral 5/10 Entry $4.95 to $3.60 Now $4.13 −16.57% ▼ −27.27% −26.71% vs SPY
- Sep 2, 202610w ago S-4/A / 425 Bearish 8/10 Entry $4.75 to $4.12 Now $4.13 +13.05% ▲ +13.26% +12.08% vs SPY
- Sep 2, 202610w ago 8-K Bullish 8/10 Entry $4.75 to $4.12 Now $4.13 −13.05% ▼ −13.26% −12.08% vs SPY
- Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
- Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
- Jun 24, 202620w ago 8-K Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers